Trial Profile

MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Filgrastim; Melphalan
Indications Multiple myeloma; Plasma cell leukaemia
Focus Therapeutic Use
Acronyms MUKnineb; OPTIMUM; UK OPTIMUM

Most Recent Events

07 Sep 2026 According to a Institute of Cancer Research Media Release, results of the study, published in The Lancet Oncology.
07 Sep 2026 Results published in the Institute of Cancer Research Media Release.
13 May 2024 Planned End Date changed from 30 Jun 2023 to 31 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com